Drug Profile
Promethazine/sumatriptan - Charleston Laboratories
Alternative Names: CL-H1T; sumatriptan succinate/promethazine HCl - Charleston LaboratoriesLatest Information Update: 21 Mar 2023
Price :
$50
*
At a glance
- Originator Charleston Laboratories
- Class Amines; Antiemetics; Antimigraines; Indoles; Phenothiazines; Small molecules; Sulfonamides
- Mechanism of Action Histamine H1 receptor antagonists; Muscarinic receptor antagonists; Serotonin 1D receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase III Migraine; Nausea and vomiting
Most Recent Events
- 21 Mar 2023 Promethazine/sumatriptan (CL H1T) is still in phase III trials for Migraine in USA (PO)
- 21 Mar 2023 Promethazine/sumatriptan (CL H1T) is still in phase III trials for Nausea and vomiting (Prevention) in USA (PO)
- 23 Feb 2021 Phase-III clinical trials in Migraine in USA (PO) (Charleston Laboratories pipeline, February 2021)